GLAXF — GSK plc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1131399 ·
United Kingdom
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 7,629,000,000 | 5,754,000,000 | 2,293,000,000 | 1,737,000,000 | 62,869,000,000 | 3,442,000,000 | 45,447,000,000 |
| Dec 2025 | 8,618,000,000 | 5,961,000,000 | 1,506,000,000 | 636,000,000 | 61,118,000,000 | 3,150,000,000 | 45,162,000,000 |
| Sep 2025 | 8,547,000,000 | 6,289,000,000 | 2,593,000,000 | 2,013,000,000 | 61,339,000,000 | 3,296,000,000 | 45,587,000,000 |
| Jun 2025 | 7,986,000,000 | 5,821,000,000 | 2,023,000,000 | 1,443,000,000 | 59,258,000,000 | 3,599,000,000 | 44,904,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$7,737,000,000
Investing CF
$-4,555,000,000
Financing CF
$-4,271,000,000
CapEx
$-2,980,000,000
Dividends Paid
$-2,595,000,000
Buybacks
$-1,456,000,000
EPS Diluted TTM
$1.33
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$11,590,000,000
Inventory
$6,157,000,000
Receivables
—
ST Investments
$1,000,000
EBIT TTM
$8,129,000,000
Pretax Income TTM
$7,437,000,000
Interest Exp TTM
$692,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$32,779,999,232
EBITDA
$11,432,999,936
Free Cash Flow
$3,019,249,920
Enterprise Value
$116,744,003,584
Total Cash
$3,443,000,064
Total Debt
$19,111,999,488
Shares Out
4,007,727,077
Trailing EPS
$1.91
Book Value
$5.96
ROE
40.9%
ROA
10.0%
Div Yield
3.57%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,667,000,000 | 8,338,000,000 | 5,716,000,000 | 61,118,000,000 | 45,162,000,000 | — | 7,741,000,000 |
| Dec 2024 | 31,376,000,000 | 5,542,000,000 | 2,575,000,000 | 59,463,000,000 | 46,377,000,000 | — | 6,554,000,000 |
| Dec 2023 | 30,328,000,000 | 7,345,000,000 | 4,928,000,000 | 59,005,000,000 | 46,210,000,000 | — | 6,768,000,000 |
| Dec 2022 | 29,324,000,000 | 6,729,000,000 | 14,956,000,000 | 60,146,000,000 | 50,050,000,000 | — | 7,403,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $991.62B | $1112.00 | — |
| JNJ | JOHNSON & JOHNSON | $563.77B | $234.20 | — |
| ABBV | AbbVie Inc. | $390.87B | $221.23 | — |
| NVS | NOVARTIS AG | $287.89B | $150.88 | — |
| MRK | Merck & Co., Inc. | $285.12B | $115.44 | — |
News headlines (Yahoo Finance, 1h cache)
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
2026-06-17 20:21 · Yahoo
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
2026-06-17 07:41 · Yahoo
[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Grow
2026-06-16 22:30 · Yahoo
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
2026-06-16 18:17 · Yahoo
MarketBeat Week in Review – 06/08 - 06/12
2026-06-13 11:00 · Yahoo
GSK Engitix Liver Fibrosis Pact Adds Early Stage Upside For Valuation
2026-06-13 01:10 · Yahoo
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
2026-06-12 13:52 · Yahoo
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
2026-06-11 17:24 · Yahoo
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
2026-06-11 16:25 · Yahoo
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
2026-06-10 18:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.